huahaipharm(SH:600521)2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥1,913,434,539.86, representing a decrease of 5.02% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2023 was ¥152,736,902.41, down 32.57% year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥146,964,128.94, a decrease of 42.34% compared to the previous year[3]. - Basic earnings per share for Q3 2023 were ¥0.11, down 31.25% year-over-year[4]. - Total operating revenue for the first three quarters of 2023 reached ¥6,207,564,556.19, an increase of 6.3% compared to ¥5,837,951,184.61 in the same period of 2022[15]. - Net profit for the first three quarters of 2023 was ¥713,177,829.99, a decrease of 11.3% from ¥804,387,508.78 in the previous year[16]. - Total profit for the first three quarters of 2023 was ¥907,967,309.17, down from ¥1,023,613,099.31 in the same period last year[16]. - Basic earnings per share for the third quarter were ¥0.50, down from ¥0.55 in the same period of 2022[17]. - Total comprehensive income for Q3 2023 was approximately ¥1.45 billion, compared to ¥832.52 million in Q3 2022, indicating a growth of 74.0%[26]. Cash Flow - The net cash flow from operating activities for Q3 2023 increased significantly by 419.10%, amounting to ¥561,084,046.23[3]. - The company experienced an increase in cash flow due to higher receipts from sales and reduced cash payments for purchases and taxes[6]. - Cash flow from operating activities generated a net amount of ¥1,451,721,440.85, significantly up from ¥598,834,358.42 in the previous year[19]. - The company recorded a total cash inflow from operating activities of ¥6,824,884,765.38, compared to ¥5,922,002,621.75 in the previous year[19]. - The company reported a net cash flow from operating activities of approximately ¥1.28 billion for the first three quarters of 2023, compared to ¥1.00 billion for the same period in 2022, an increase of 27.3%[27]. - Cash flow from investment activities showed a net outflow of approximately ¥801.96 million in Q3 2023, an improvement from a net outflow of ¥956.92 million in Q3 2022[28]. - Cash flow from financing activities resulted in a net outflow of approximately ¥531.65 million in Q3 2023, compared to a net outflow of ¥197.09 million in Q3 2022[28]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥18,431,420,846.16, an increase of 1.54% from the end of the previous year[4]. - The company's current assets decreased to RMB 7,646,144,887.82 from RMB 7,907,175,521.63, reflecting a decline of about 3.29%[12]. - The cash and cash equivalents stood at RMB 1,089,955,831.98, down from RMB 1,365,152,641.03, indicating a decrease of approximately 20.19%[11]. - The company's inventory increased to RMB 3,519,023,267.04 from RMB 3,374,697,311.70, marking a rise of about 4.28%[12]. - Total liabilities decreased to RMB 10,176,645,572.70 from RMB 10,406,116,493.24, a reduction of approximately 2.21%[13]. - The company's equity attributable to shareholders rose to RMB 8,076,555,134.78 from RMB 7,546,549,238.90, an increase of about 7.02%[14]. - The company's retained earnings increased to RMB 4,614,137,180.70 from RMB 4,245,727,768.72, representing a growth of approximately 8.67%[14]. - The total current assets increased to ¥7,976,906,614.81 from ¥7,265,247,058.03, reflecting a growth of approximately 9.8% year-over-year[22]. - The total liabilities decreased to ¥7,815,879,715.32 from ¥7,944,976,145.97, showing a reduction of approximately 1.6%[23]. - The company's retained earnings rose to ¥6,548,440,507.43 from ¥5,450,841,442.79, marking an increase of approximately 20.2%[23]. Expenses - Total operating costs increased to ¥5,237,280,573.21, up 11.2% from ¥4,706,550,884.92 year-on-year[15]. - Research and development expenses were ¥667,445,298.33, slightly down from ¥670,476,442.29 in the same period last year[15]. - The company reported a decrease in financial expenses, with interest expenses at ¥181,880,354.28, compared to ¥163,465,092.73 in the previous year[15]. - Research and development expenses for the first three quarters were ¥293,032,261.11, slightly down from ¥299,112,514.85 in the same period last year[24]. - The company reported a decrease in income tax expenses to approximately ¥67.02 million in Q3 2023 from ¥95.07 million in Q3 2022, a reduction of 29.5%[25]. Foreign Exchange and Other Factors - The company reported increased foreign exchange losses, which contributed to the decline in net profit compared to the previous year[7]. - Non-recurring gains and losses for Q3 2023 totaled ¥5,772,773.47, compared to a loss of ¥47,262,521.97 for the year-to-date[5]. - Interest income for Q3 2023 was approximately ¥79.69 million, up from ¥45.59 million in Q3 2022, representing a year-over-year increase of 74.8%[25]. - The company received cash from sales and services amounting to approximately ¥4.21 billion in the first three quarters of 2023, compared to ¥3.44 billion in the same period of 2022, a growth of 22.4%[27].